We came across a bullish thesis on PROCEPT BioRobotics Corporation on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on PRCT. PROCEPT BioRobotics Corporation's share was trading at $29.21 as of February 9th. Is Intuitive Surgical’s (ISRG) Valuation Limiting Further Upside After Earnings? Master Video/Shutterstock.com PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in t ...

​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ahead of its fiscal Q4 2025 earnings, expected to be released on February 24, 2026. The Street expects the company to post quarterly revenue of around $372.87 million and a GAAP EPS of $1.56. ​Recently, on January 26, Ryan Zimmerman from BTIG maintained a Hold rating on the stock without disclosing any price targets. Earlier on Decemb ...

分组1 - IQVIA Holdings reported quarterly earnings of $3.42 per share, exceeding the Zacks Consensus Estimate of $3.4 per share, and showing an increase from $3.12 per share a year ago, representing an earnings surprise of +0.50% [1] - The company achieved revenues of $4.36 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.83%, and up from $3.96 billion in the same quarter last year [2] - IQVIA has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 10.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $4.04 billion, and for the current fiscal year, it is $12.93 on revenues of $17.03 billion [7] 分组3 - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for IQVIA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

分组1 - Steris reported quarterly earnings of $2.53 per share, matching the Zacks Consensus Estimate, and showing an increase from $2.32 per share a year ago, with an earnings surprise of -0.10% [1] - The company achieved revenues of $1.5 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.08%, and up from $1.37 billion year-over-year [2] - Steris has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] 分组2 - The stock has gained approximately 3.2% since the beginning of the year, outperforming the S&P 500's gain of 1.1% [3] - The current consensus EPS estimate for the upcoming quarter is $2.88 on revenues of $1.6 billion, and for the current fiscal year, it is $10.23 on revenues of $5.93 billion [7] - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8]

Group 1 - The company, PROCEPT BioRobotics Corporation, will report its financial results for Q4 2025 on February 24, 2026, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1] - An in-person investor day event is scheduled for February 25, 2026, at NASDAQ Headquarters in New York City, starting at 8:00 a.m. Eastern Time, with advance registration recommended [2] - Live webcasts of both the financial results and investor day will be available on the company's website, with recordings archived for at least 90 days [3] Group 2 - PROCEPT BioRobotics aims to revolutionize BPH treatment globally by providing advanced robotic solutions that enhance patient outcomes and deliver value [4] - The company manufactures the AQUABEAM® and HYDROS® Robotic Systems, with the HYDROS system being the only AI-powered technology for Aquablation therapy, designed for effective treatment of lower urinary tract symptoms in men [4] - BPH is the most common prostate disease, affecting approximately 40 million men in the United States [4]

Company Overview - Procept BioRobotics Corporation (NASDAQ:PRCT) is a surgical robotics company focused on developing transformative solutions in urology both in the US and internationally [4]. Analyst Ratings and Price Targets - Truist analyst Richard Newitter lowered the price target on Procept BioRobotics to $47 from $50 while maintaining a Buy rating, indicating optimism about the MedTech sector despite caution regarding capital allocation [1]. - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a price target of $62, citing confidence in the company's growth potential through 2026 and 2027 based on consultations with key opinion leaders [2]. - Bank of America downgraded Procept BioRobotics to Neutral from Buy with a reduced price target of $38, down from $55, highlighting concerns over slowing utilization growth and operational challenges [3]. Market Potential and Growth Drivers - Procept's aquablation technology is noted for its significant market potential in treating benign prostatic hyperplasia, although there are concerns about the simultaneous slowdown in system sales and procedure volume [3]. - The company is focusing on initiatives to increase usage of its current hardware and exploring new system placements in untapped markets, which could drive long-term revenue growth [2]. Industry Context - The MedTech sector is viewed as potentially acting as a source of funds rather than a primary destination for new capital, with a preference for companies that have specific catalysts for growth [1].

Core Insights - Intuitive Surgical (ISRG) stock has increased by 32.4% over the past three months, currently trading at $592.85, just 3.8% below its all-time high of $616 reached in February 2025, reflecting strong investor confidence following robust third-quarter earnings [1][19] Financial Performance - ISRG has outperformed peers like Medtronic (MDT) and PROCEPT BioRobotics (PRCT) in the past three months, with MDT gaining 2.5% and PRCT declining by 0.1% [2] - Total worldwide procedures grew by 20% year over year, driven by a 19% increase in da Vinci procedures and a 52% increase in Ion procedures [2][7] Growth Drivers - Procedure growth is a key component of Intuitive Surgical's long-term value creation, with strong performance noted across various geographies and specialties, including U.S. benign general surgery and international growth in general surgery, gynecology, colorectal, and thoracic procedures [3] - Average system utilization increased by 4% for da Vinci multiport, 35% for SP, and 14% for Ion, indicating rising throughput within the installed base [4] Product Development - The launch of da Vinci 5 is a significant catalyst for revenue growth, with 240 systems placed in Q3, bringing the global installed base to 929 systems [5][7] - Approximately 85% of ISRG's revenues come from recurring sales, supported by features and upgrades of da Vinci 5 [7][9] Competitive Landscape - Rising competition in surgical robotics includes Medtronic's Hugo platform and Procept BioRobotics' AI-powered HYDROS system, which could impact Intuitive Surgical's market dominance [14][16] Future Outlook - Estimates for Intuitive Surgical's 2025 earnings have increased by 8.5% to $8.65 per share, indicating bullish sentiment [17] - Sustained procedure growth, rising utilization, and accelerating da Vinci 5 adoption position the company for durable growth into 2026 [20]

Core Viewpoint - Procept Biorobotics Corp. (NASDAQ:PRCT) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by bullish analyst ratings and growth prospects [1][3]. Group 1: Analyst Ratings and Price Targets - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a target price of $62, indicating an upside potential of over 93% from current levels [1][2]. - As of December 19, 80% of 10 analyst ratings for the stock were Buy calls, with a 1-year average price target of $51.75, suggesting over 61% upside potential [3]. Group 2: Company Overview and Growth Prospects - Procept Biorobotics Corp. specializes in surgical robotics, focusing on robotic treatments for male urological health, particularly through its flagship Aquablation® therapy [4]. - The company aims to increase the utilization of its current installed base and expand into new markets, with expectations of turning profitable by 2027 due to revenue growth, improved gross margins, and operational efficiencies [2].

Core Viewpoint - PROCEPT BioRobotics Corporation is recognized as a fast-growing small-cap stock, with analysts maintaining a Buy rating despite a price target reduction from $55 to $50 following strong fiscal Q3 2025 results [1][2]. Financial Performance - The company reported a revenue increase of 42.76% to $83.33 million, exceeding estimates by $2.56 million [2]. - The earnings per share (EPS) of negative $0.38 also surpassed consensus expectations by $0.04 [2]. Product and Market Demand - Revenue growth is attributed to strong demand for the HYDROS Robotic System, which saw a year-over-year growth of 43%, alongside increasing adoption of Aquablation therapy [2][3]. - PROCEPT BioRobotics develops the AQUABEAM Robotic System, a surgical robot that utilizes real-time imaging and a heat-free water jet for precise prostate tissue removal [4]. Analyst Insights - Analyst Matthew O'Brien noted that the company's Q3 performance was better than expected, with sales forecasts for 2025 and 2026 aligning closely with Wall Street's expectations [3]. - Concerns regarding soft utilization performance and investor destocking are viewed as temporary issues, attributed to internal changes within the company [3].

Core Insights - Stereotaxis (STXS) has launched its Synchrony system in Europe and submitted a 510(k) application to the U.S. FDA, aiming to modernize interventional cath labs with a unified digital interface [1][5] - The Synchrony system enhances workflow, visualization, and connectivity, positioning Stereotaxis to expand its market presence in both robotic and non-robotic cath labs [2][4] Product Features - Synchrony features a 55-inch ultra-high-definition 4K display that integrates multiple system feeds into a single interface, providing near-zero latency video streams and customizable layouts [3] - The system is paired with SynX, a secure cloud-based application that enables remote connectivity, collaboration, and real-time monitoring, compliant with HIPAA and GDPR standards [3][4] Strategic Vision - Synchrony and SynX are foundational platforms designed to support future advancements, including AI-driven automation and long-distance robotic procedures, aligning with Stereotaxis' long-term digital surgery vision [4] - The CE Mark approval allows for commercial rollout in EU markets, while the FDA submission paves the way for potential entry into the U.S. market, enhancing Stereotaxis' geographic reach [5] Competitive Landscape - Stereotaxis competes with key players like Intuitive Surgical (ISRG), which has advanced its da Vinci 5 platform with new software features and gained CE Mark approval for broader international rollout [6][7] - Microbot Medical (MBOT) has achieved FDA clearance for its LIBERTY Endovascular Robotic System, marking a significant milestone in the endovascular robotics market [8][10] - PROCEPT BioRobotics (PRCT) reported strong revenue growth and wider adoption of its Aquablation therapy, indicating a competitive environment in robotic-assisted surgical solutions [11][12]